Trial Profile
Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms NLCTG1501-BM
- 12 Dec 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2018 New trial record